Justin Burgess - Mar 1, 2024 Form 4 Insider Report for DYNAVAX TECHNOLOGIES CORP (DVAX)

Role
Chief Accounting Officer
Signature
/s/ JUSTIN BURGESS
Stock symbol
DVAX
Transactions as of
Mar 1, 2024
Transactions value $
-$188,091
Form type
4
Date filed
3/4/2024, 05:25 PM
Previous filing
Feb 20, 2024
Next filing
Mar 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DVAX Common Stock Options Exercise $48.2K +4.33K +32.28% $11.12 17.8K Mar 1, 2024 Direct F1
transaction DVAX Common Stock Options Exercise $26K +2.77K +15.58% $9.41 20.5K Mar 1, 2024 Direct F1
transaction DVAX Common Stock Sale -$90.8K -7.1K -34.6% $12.78 13.4K Mar 1, 2024 Direct F2, F3
transaction DVAX Common Stock Sale -$172K -13.4K -100% $12.78 0 Mar 1, 2024 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DVAX Stock Options (Right to Buy) Options Exercise $0 -4.33K -33.34% $0.00 8.67K Mar 1, 2024 Common Stock 0 $11.12 Direct F1, F4
transaction DVAX StockOptions (Right to Buy) Options Exercise $0 -2.77K -100% $0.00* 0 Mar 1, 2024 Common Stock 0 $9.41 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Code M - Exercise or conversion of derivative security
F2 Code S - Open market or private sale of non-derivative or derivative security
F3 This transaction was executed in multiple trades at prices ranging from $12.73 to $12.81; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
F4 This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 16, 2023, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter.
F5 This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 3, 2021, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter.